-
1
-
-
33845286942
-
Vascular disrupting agents
-
Lippert JW III. Vascular disrupting agents. Bioorg Med Chem 2007;15:605-15.
-
(2007)
Bioorg Med Chem
, vol.15
, pp. 605-615
-
-
Lippert III, J.W.1
-
2
-
-
65549164757
-
Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies
-
Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009;90:284-94.
-
(2009)
Int J Exp Pathol
, vol.90
, pp. 284-294
-
-
Kanthou, C.1
Tozer, G.M.2
-
3
-
-
0037115398
-
ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature
-
Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
-
(2002)
Cancer Res
, vol.62
, pp. 7247-7253
-
-
Davis, P.D.1
Dougherty, G.J.2
Blakey, D.C.3
-
5
-
-
34247249906
-
Vascular disrupting agents in clinical development
-
DOI 10.1038/sj.bjc.6603694, PII 6603694
-
Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65. (Pubitemid 46625071)
-
(2007)
British Journal of Cancer
, vol.96
, Issue.8
, pp. 1159-1165
-
-
Hinnen, P.1
Eskens, F.A.L.M.2
-
6
-
-
33645728030
-
Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?
-
van Heeckeren WJ, Bhakta S, Ortiz J, et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 2006;24:1485-8.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1485-1488
-
-
Van Heeckeren, W.J.1
Bhakta, S.2
Ortiz, J.3
-
7
-
-
1642494772
-
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer
-
Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 96-100
-
-
Cooney, M.M.1
Radivoyevitch, T.2
Dowlati, A.3
-
9
-
-
0036512208
-
New functions for the matrix metalloproteinases in cancer progression
-
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.3
, pp. 161-174
-
-
Egeblad, M.1
Werb, Z.2
-
10
-
-
33644545381
-
Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
-
Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 227-239
-
-
Overall, C.M.1
Kleifeld, O.2
-
11
-
-
26644464600
-
Identification of MMP-15 as an anti-apoptotic factor in cancer cells
-
Abraham R, Schafer J, Rothe M, Bange J, Knyazev P, Ullrich A. Identification of MMP-15 as an anti-apoptotic factor in cancer cells. J Biol Chem 2005;280:34123-32.
-
(2005)
J Biol Chem
, vol.280
, pp. 34123-34132
-
-
Abraham, R.1
Schafer, J.2
Rothe, M.3
Bange, J.4
Knyazev, P.5
Ullrich, A.6
-
13
-
-
8744221615
-
Involvement of Membrane-Type Matrix Metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial Cells: Role of MT3-MMP
-
DOI 10.1210/jc.2004-0860
-
Plaisier M, Kapiteijn K, Koolwijk P, et al. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J Clin Endocrinol Metab 2004;89:5828-36. (Pubitemid 39518478)
-
(2004)
Journal of Clinical Endocrinology and Metabolism
, vol.89
, Issue.11
, pp. 5828-5836
-
-
Plaisier, M.1
Kapiteijn, K.2
Koolwijk, P.3
Fijten, C.4
Hanemaaijer, R.5
Grimbergen, J.M.6
Mulder-Stapel, A.7
Quax, P.H.A.8
Helmerhorst, F.M.9
Van Hinsbergh, V.W.M.10
-
14
-
-
15244352321
-
Membrane type-matrix metalloproteinases and tumor progression
-
Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005;87:329-42.
-
(2005)
Biochimie
, vol.87
, pp. 329-342
-
-
Sounni, N.E.1
Noel, A.2
-
15
-
-
0036109679
-
MT-MMPs play pivotal roles in cancer dissemination
-
DOI 10.1023/A:1015527220537
-
Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15. (Pubitemid 34555419)
-
(2002)
Clinical and Experimental Metastasis
, vol.19
, Issue.3
, pp. 209-215
-
-
Yana, I.1
Seiki, M.2
-
16
-
-
0037426578
-
Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion
-
Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003;194:1-11.
-
(2003)
Cancer Lett
, vol.194
, pp. 1-11
-
-
Seiki, M.1
-
17
-
-
77049106382
-
Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy
-
Strongin AY. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 2010;1803:133-41.
-
(2010)
Biochim Biophys Acta
, vol.1803
, pp. 133-141
-
-
Strongin, A.Y.1
-
18
-
-
44349156127
-
MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease
-
DOI 10.1038/sj.onc.1210982, PII 1210982
-
Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008;27:3274-81. (Pubitemid 351733384)
-
(2008)
Oncogene
, vol.27
, Issue.23
, pp. 3274-3281
-
-
Szabova, L.1
Chrysovergis, K.2
Yamada, S.S.3
Holmbeck, K.4
-
19
-
-
14944357237
-
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells
-
Soulie P, Carrozzino F, Pepper MS, Strongin AY, Poupon MF, Montesano R. Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene 2005;24:1689-97.
-
(2005)
Oncogene
, vol.24
, pp. 1689-1697
-
-
Soulie, P.1
Carrozzino, F.2
Pepper, M.S.3
Strongin, A.Y.4
Poupon, M.F.5
Montesano, R.6
-
20
-
-
33847133438
-
Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo
-
DOI 10.1186/1471-2407-6-52
-
Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52. (Pubitemid 46277066)
-
(2006)
BMC Cancer
, vol.6
, pp. 52
-
-
Zhang, W.1
Matrisian, L.M.2
Holmbeck, K.3
Vick, C.C.4
Rosenthal, E.L.5
-
21
-
-
22244472310
-
Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts
-
Rutkauskaite E, Volkmer D, Shigeyama Y, et al. Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2005;52:2010-4.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 2010-2014
-
-
Rutkauskaite, E.1
Volkmer, D.2
Shigeyama, Y.3
-
22
-
-
9444290419
-
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP
-
Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769-81.
-
(2004)
J Cell Biol
, vol.167
, pp. 769-781
-
-
Sabeh, F.1
Ota, I.2
Holmbeck, K.3
-
23
-
-
0346363608
-
Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors
-
Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003;22:8716-22.
-
(2003)
Oncogene
, vol.22
, pp. 8716-8722
-
-
Ueda, J.1
Kajita, M.2
Suenaga, N.3
Fujii, K.4
Seiki, M.5
-
24
-
-
20344361933
-
Metalloproteinases and their inhibitors in tumor angiogenesis
-
Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-60.
-
(2005)
Int J Cancer
, vol.115
, pp. 849-860
-
-
Handsley, M.M.1
Edwards, D.R.2
-
25
-
-
60649108677
-
Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis
-
Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-26.
-
(2009)
Cancer Res
, vol.69
, pp. 1517-1526
-
-
Devy, L.1
Huang, L.2
Naa, L.3
-
26
-
-
18344366604
-
MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression
-
Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
-
(2002)
FASEB J
, vol.16
, pp. 555-564
-
-
Sounni, N.E.1
Devy, L.2
Hajitou, A.3
-
28
-
-
0036041236
-
Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy
-
Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34:581-92.
-
(2002)
Drug Metab Rev
, vol.34
, pp. 581-592
-
-
Patterson, L.H.1
-
29
-
-
39749101689
-
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study
-
Albertella MR, Loadman PM, Jones PH, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 2008;14:1096-104.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 1096-1104
-
-
Albertella, M.R.1
Loadman, P.M.2
Jones, P.H.3
-
30
-
-
14844303761
-
Capecitabine: A review
-
Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
-
(2005)
Clin Ther
, vol.27
, pp. 23-44
-
-
Walko, C.M.1
Lindley, C.2
-
31
-
-
41649103896
-
Tumour endoproteases: The cutting edge of cancer drug delivery?
-
Atkinson JM, Siller CS, Gill JH. Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol 2008;153:1344-52.
-
(2008)
Br J Pharmacol
, vol.153
, pp. 1344-1352
-
-
Atkinson, J.M.1
Siller, C.S.2
Gill, J.H.3
-
32
-
-
16744368637
-
United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
-
second edition
-
Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
-
(1998)
Br J Cancer
, vol.77
, pp. 1-10
-
-
Workman, P.1
Twentyman, P.2
Balkwill, F.3
-
33
-
-
34447293780
-
Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity
-
Atkinson JM, Pennington CJ, Martin SW, et al. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 2007;43:1764-71.
-
(2007)
Eur J Cancer
, vol.43
, pp. 1764-1771
-
-
Atkinson, J.M.1
Pennington, C.J.2
Martin, S.W.3
-
34
-
-
0037359601
-
Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells
-
Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45.
-
(2003)
Mol Cancer Res
, vol.1
, pp. 333-345
-
-
Nuttall, R.K.1
Pennington, C.J.2
Taplin, J.3
-
35
-
-
77956296475
-
MMP activated vascular disrupting agents
-
Gill JH, Loadman P, Falconer RA, Patterson LH, Atkinson JM, Bibby MC inventors; University of Bradford, applicant. UK patent WO2008125800. October 23
-
Gill JH, Loadman P, Falconer RA, Patterson LH, Atkinson JM, Bibby MC inventors; University of Bradford, applicant. MMP activated vascular disrupting agents. UK patent WO2008125800. 2008 October 23.
-
(2008)
-
-
-
36
-
-
0021061819
-
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
-
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
-
(1983)
Journal of Immunological Methods
, vol.65
, Issue.1-2
, pp. 55-63
-
-
Mosmann, T.1
-
37
-
-
35148827486
-
Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models
-
Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol 2007;31:353-60.
-
(2007)
Int J Oncol
, vol.31
, pp. 353-360
-
-
Shnyder, S.D.1
Cooper, P.A.2
Millington, N.J.3
Pettit, G.R.4
Bibby, M.C.5
-
38
-
-
0032499266
-
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket
-
Yamamoto M, Tsujishita H, Hori N, et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem 1998;41:1209-17.
-
(1998)
J Med Chem
, vol.41
, pp. 1209-1217
-
-
Yamamoto, M.1
Tsujishita, H.2
Hori, N.3
-
39
-
-
0032842567
-
Tumor targeting with a selective gelatinase inhibitor
-
Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
-
(1999)
Nat Biotechnol
, vol.17
, pp. 768-774
-
-
Koivunen, E.1
Arap, W.2
Valtanen, H.3
-
40
-
-
0026742089
-
The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours
-
Quinn PK, Bibby MC, Cox JA, Crawford SM. The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer 1992;66:323-30.
-
(1992)
Br J Cancer
, vol.66
, pp. 323-330
-
-
Quinn, P.K.1
Bibby, M.C.2
Cox, J.A.3
Crawford, S.M.4
-
41
-
-
0023935131
-
Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
-
Smith KA, Hill SA, Begg AC, Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 1988;57:247-53. (Pubitemid 18096329)
-
(1988)
British Journal of Cancer
, vol.57
, Issue.3
, pp. 247-253
-
-
Smith, K.A.1
Hill, S.A.2
Begg, A.C.3
Denekamp, J.4
-
42
-
-
49149106418
-
Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells
-
Ingvarsen S, Madsen DH, Hillig T, et al. Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biol Chem 2008;389:943-53.
-
(2008)
Biol Chem
, vol.389
, pp. 943-953
-
-
Ingvarsen, S.1
Madsen, D.H.2
Hillig, T.3
-
43
-
-
9944223360
-
Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice
-
Drew AF, Blick TJ, Lafleur MA, et al. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Oncol 2004;95:437-48.
-
(2004)
Gynecol Oncol
, vol.95
, pp. 437-448
-
-
Drew, A.F.1
Blick, T.J.2
Lafleur, M.A.3
-
44
-
-
34249744576
-
Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells
-
Yana I, Sagara H, Takaki S, et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 2007;120:1607-14.
-
(2007)
J Cell Sci
, vol.120
, pp. 1607-1614
-
-
Yana, I.1
Sagara, H.2
Takaki, S.3
-
45
-
-
34948862788
-
Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
-
Martinelli M, Bonezzi K, Riccardi E, et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007;97:888-94.
-
(2007)
Br J Cancer
, vol.97
, pp. 888-894
-
-
Martinelli, M.1
Bonezzi, K.2
Riccardi, E.3
-
46
-
-
62549085978
-
A mathematical model of doxorubicin penetration through multicellular layers
-
Evans CJ, Phillips RM, Jones PF, et al. A mathematical model of doxorubicin penetration through multicellular layers. J Theor Biol 2009;25:598-608.
-
(2009)
J Theor Biol
, vol.25
, pp. 598-608
-
-
Evans, C.J.1
Phillips, R.M.2
Jones, P.F.3
|